Pregnant people with existing medical conditions face higher likelihoods of severe infectious illness and adverse pregnancy outcomes, making tailored vaccination programs essential. Evidence from Tom T. Shimabukuro, Centers for Disease Control and Prevention, indicates active surveillance systems like v-safe can detect safety signals for vaccines administered during pregnancy, supporting targeted program design. The American College of Obstetricians and Gynecologists through Laura M. Riley emphasizes integrating vaccination into routine prenatal care to improve uptake and outcomes.
Risk stratification and individualized schedules
Effective tailoring begins with risk stratification that accounts for specific comorbidities such as obesity, diabetes, hypertension, and immunosuppression. Clinical teams should perform structured assessments early in pregnancy to identify elevated vulnerability and prioritize vaccines that reduce the most immediate maternal and fetal risks. Timing can matter: optimizing administration during antenatal visits minimizes missed opportunities, and selection between vaccine platforms should follow current safety guidance. Evidence for some vaccine–pregnancy interactions remains limited, so decisions often balance known risks of infection with available safety data.
Multidisciplinary delivery and surveillance
Programs should adopt multidisciplinary care models linking obstetrics, primary care, infectious disease, and pharmacy. Embedding vaccination into antenatal clinics reduces structural barriers and aligns with recommendations from major professional bodies to offer vaccines during routine visits. Active surveillance and registries, exemplified by the CDC v-safe pregnancy registry described by Tom T. Shimabukuro, provide ongoing safety monitoring and inform refinement of recommendations. Real-world data collection is particularly important for rare adverse events and for populations underrepresented in clinical trials.
Cultural, territorial, and access considerations
Tailoring must also address social determinants: language-appropriate counseling, community engagement, and outreach to regions with limited access are critical to equitable uptake. In settings with high burdens of infectious comorbidity or constrained cold-chain capacity, program design should prioritize thermostable formulations and simplified schedules. Failure to tailor can increase risks of severe maternal illness, preterm birth, and wider health inequities.
Practical components include shared decision-making conversations rooted in up-to-date guidance from professional institutions, clear documentation in prenatal records, and flexible delivery options such as co-administration with routine antenatal vaccines. As evidence evolves, continuous feedback between surveillance data and clinical guidance ensures programs remain both safe and responsive to the needs of pregnant people with comorbidities.